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Abstract 
Influenza A is the most pandemic-prone class of the influenza virus, with new strains 
emerging every year. Though vaccination is promoted as the vanguard against wide-spread 
infection, it is not enough to withstand mutating virus strains. Current antiviral therapeutics are 
frequently falling to resistant virus types. Better antiviral therapies are needed, and nanotechnology 
can be part of the solution.  
Mucoadhesive nanoparticles (MNPs) are nanoparticles which bind to the mucus 
membrane. Polymeric micellar MNPs made from poly(lactic acid), dextran, and phenylboronic 
acid have been quite successful in ocular drug delivery to treat dry-eye disease. Their mucus-
binding ability points to applications in treatments for other diseases which target the mucus 
membrane, such as influenza A. 
This thesis aims to determine the potential for MNPs as a new class of antiviral therapeutic. 
A review of current literature highlights the use of nanoparticles in influenza treatment, and the 
work in this thesis draws on this information. Binding kinetics studies are conducted to determine 
the strength of MNPs’ binding with mucin/sialic acid, and compare this to that of sialic acid-
influenza as found in literature. The effect of aerosolization on the MNPs is studied in terms of 
their key characteristics such as morphology and drug encapsulation in order to determine their 
suitability as a delivery vehicle to the pulmonary tract. The binding kinetics studies also provide 
another avenue of study regarding prediction of in vivo mucoadhesion using in vitro techniques.  
Overall these studies present a promising basis for the use of MNPs as a novel antiviral 
therapeutic. Through detailed binding kinetics and aerosolization studies, the first in vitro steps 
have been established for their viable use. Further steps involving in vitro and in vivo studies are 
discussed in the conclusions.  
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Chapter 1. Introduction 
1.1. Background 
Mucoadhesive nanoparticles (MNPs) are a class of nanoparticles (NPs) which bind to the 
mucus membrane throughout the body [1]–[3]. Our research group has developed MNPs for 
targeted drug delivery to the ocular surface [4]. These MNPs are polymeric micelles with a 
hydrophobic core of poly(lactic acid) (PLA), a hydrophilic shell of dextran, and a corona of 








The MNPs are currently used for ocular drug delivery to treat dry-eye disease. Cyclosporine A 
(CsA, the active ingredient in Restasis®) is encapsulated in the hydrophobic interior of the MNPs, 
and is delivered to the ocular surface by eye drops, as seen in Figure 2. 
Figure 1. Schematic of MNPs with hydrophobic PLA, 
hydrophilic dextran, and PBA grafts 
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Figure 2. MNP delivery to the ocular surface. Mucoadhesive binding occurs between the MNPs 
and the surface, allowing it stay and deliver CsA. [4] 
 
The mucoadhesive binding occurs between the PBA grafts on the MNPs and N-Acetylneuraminic 
acid, or sialic acid as it is more often called. Sialic acid (SA) is the terminal monosaccharide on 
the mucus membrane [5]. The binding is shown in Figure 3. 
 
Figure 3. PBA binding to SA 
PBA’s hydroxyl groups bind to SA through covalent diol-diol binding, allowing the MNPs to stay 
on the mucus membrane and deliver drugs effectively over a longer period of time than commercial 
options [4]. 
As MNPs are quite proficient at binding to the ocular surface, it was hypothesized that their 
mucoadhesive binding prowess could be applied to other mucus membranes. Mucus membranes 
protect much of the internal cavities in the human body, varying from the ocular surface to the 
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gastric surface, to the vaginal surface and more [6]. One such application for MNPs is the 
pulmonary tract, with its mucus membrane protecting the underlying epithelial cells. The 










 Both mucus membranes are layered above epithelial cells with goblet cells interspersed 
throughout, and are made of similar mucin structures with SA as the terminal monosaccharide 
group [5]. These similarities allow for a comparison of MNPs’ ability to bind to the pulmonary 
tract mucus membrane in a similar vein to its ocular membrane binding, and to be of use in treating 
diseases which infect this location. 
A common illness involving the pulmonary tract is the influenza A virus, which enters the 
body through inhalation. Influenza A is from the orthomyxovirus family, which consists of viruses 
composed of a lipid envelope with negative-sense RNA inside, and is responsible for 3 to 5 million 
infections and 250 000 to 500 000 deaths worldwide annually [7]. With such a large scope, 
effective prevention and treatment mechanisms are necessary to combat its spread. While vaccines 
are an important component to influenza care, they are limited in their abilities to treat a broad-
Figure 4. Ocular mucosal membrane (left) compared to pulmonary tract 
mucosal membrane (right) [116][117] 
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spectrum of viruses as they are specifically designed to inhibit the top contenders for pandemics 
every year [8], and so are ineffective against the antigenic drift which occurs throughout the 
season. Current antiviral therapeutics are limited in their efficacy and have spurred resistance 
among many virus strains to their antiviral mechanisms [9]–[11]. In short, new methods and 
materials are needed to combat influenza viruses. 
MNPs can pave the way for new antiviral treatments by being both a delivery vehicle for 
drugs, and a steric hindrance for actual influenza virus binding. Influenza infection starts with the 
binding of the virus particle to SA on the mucus membrane, which is also the target receptor for 
MNPs. If this binding can be blocked by MNPs while they concurrently deliver antiviral drugs, 
this will be a new approach to antiviral therapeutics which will minimize the likelihood of 
resistance cropping up due to the multivalent strategy used.  
1.2. Research objectives 
The goal of this research was to determine the feasibility of using MNPs for a new 
application: treatment of the influenza A virus. This was done by: 
1. Establishing qualitative binding kinetics studies to compare binding of MNPs vs. 
control NPs to mucin 
2. Defining a straightforward, facile method to determine binding kinetics quantitatively 
between MNPs and SA and comparing this to influenza-SA from literature 
3. Aerosolizing MNPs and determining if they retain similar properties from pre-
aerosolization (morphology, encapsulation efficiency, drug release) 
1.3. Thesis outline 
This thesis is written as follows: 
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Chapter 1 provides an overview of the thesis itself, along with background on the topic. 
This serves as a framework for the research presented. 
Chapter 2 is an in-depth literature review on the current research into using NPs for 
treatment of influenza A. The infection mechanism is presented, along with shortcomings in 
current treatment methods. Silver, gold, metal oxide, and polymeric NPs are reviewed. 
Chapter 3 discusses the first step in assessing the viability of MNPs as an antiviral 
treatment, which is to obtain quality binding kinetics data. Localized surface plasmon resonance 
(LSPR) acquires real-time binding information between the MNPs and mucin, allowing 
comparisons to the binding between PLA-Dex NPs (control NPs with no PBA on the surface) and 
mucin. Data which shows binding with mucin is crucial as this mimics in vivo systems more 
accurately than simply using SA. From there, quantitative binding kinetics data is obtained in the 
form of the association constant KA. Fluorescence spectroscopy is used to determine this data. The 
results are compared to literature values for influenza and SA in order to determine the 
appropriateness of using MNPs to combat influenza. An off-shoot of these binding kinetics 
methods was discovered where they can be used to correlate in vitro and in vivo mucoadhesion of 
the MNPs. The preliminary data is discussed here. 
Chapter 4 delves into aerosolization of the MNPs in preparation for their eventual 
pulmonary delivery. MNPs’ characteristics and properties are examined before and after 
aerosolization to determine their feasibility in carrying antiviral drugs. Their morphology, 
encapsulation efficiencies, drug loading, and release capabilities are studied. CsA is encapsulated 
as a model drug, as it aids with pulmonary function and has previously been encapsulated in MNPs. 




Chapter 2. Literature Review 
This review aims to present a comprehensive picture of influenza A treatment with NPs, 
while framing it in the larger context of the influenza infection mechanism and shortcomings of 
current antiviral therapeutics. Influenza A is the primary focus of this review, as it is the most 
wide-spread and harmful variant of influenza for humans, and evolves at a much more rapid rate 
than influenza B, the other pandemic-causing class of influenza [12][13]. 
2.1. The influenza A virus 
The influenza A virus is a roughly spherical, 80-120 nm particle. It consists of a viral lipid 
envelope containing ribonucleoproteins (RNPs) made up of the negative-sense genomic RNA 
which code for the virus proteins and RNA polymerase. There are two major glycoproteins 
(hemagglutinin and neuraminidase) and matrix ion channels traversing the lipid envelope [14][15]. 
Hemagglutinin (HA) and neuraminidase (NA) make up the majority of the proteins available on 
the surface, while the matrix (M2) ion channels appear in a ratio of one M2 channel to 









Figure 5. Influenza virus particle [118] 
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 HA and NA present different antigens depending on the virus type, and antibodies can be 
generated for these specific antigens. Therefore, viruses are classified based off their antigenic 
types (i.e. H1N1 for the H1 HA, N1 NA protein) [17]. HA is primarily responsible for binding the 
virus particle to the mucosal membrane and human epithelial cells in the pulmonary tract, whereas 
NA is responsible for allowing the newly-replicated virions to exit the cell [18]. HA is a trimer 
with 2 distinct regions, a stem with alpha-helices and a globular head with antiparallel beta sheets. 
Binding of the virus particle to the mucosal membrane/epithelial cells occurs with the head [19]. 
NA is a tetramer with a mushroom shape, with a transmembrane stem. It is responsible for cleaving 
the target receptors from the cells in order to release the budding virions [20]. The M2 ion channel 
is a tetramer transmembrane protein, and is involved in viral entry into cells via the endosome 
[21]. There are four main stages to influenza A infection: virus binding to epithelial cells, viral 
entry into the cell, viral replication within the cell, and virus release outside of the cell [22]. Each 
stage is elucidated below. 
 Virus binding to epithelial cells 
The influenza virus is transmitted person-to-person through either direct contact with an 
infected person, aerosol inhalation, or indirect contact with a contaminated surface [23]. Upon 
entry into the pulmonary tract, the virus particles come in contact with the mucosal membrane, 
and through it, the target epithelial cells. 
As mentioned before, HA is the primary component of the virus responsible for binding to 
the cell membrane. Its target receptor is sialic acid, the terminal monosaccharide present on the 
cell membrane in epithelial cells [5]. HA binds to SA through hydrophobic interactions and 
hydrogen bonding with a conserved area of its globular head region [24][25]. The second carbon 
of SA can be bound to galactose at either its third or sixth carbon, leading to either α-2,3 or α-2,6 
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linkages. Different HAs prefer to bind to different linkage types, and as α-2,6 is the most prevalent 
type in human epithelial cells, influenza subtypes with HAs that bind to them are the most common 
for pandemics in humans [26]. 
Upon binding, the HA molecule is endocytosed, which causes its cleavage by serine 
proteases into its two subunits, HA1 and HA2. HA1 is the location of the SA binding site, and 
HA2 is a fusion peptide which helps with binding to the endosomal membrane [27]. 
 Viral entry into epithelial cells 
The endocytosis of the virus is dependent on the acidity of the endosomal environment. It 
is the acidity itself which causes the cleavage of the HA protein discussed in 2.1.1. The HA2 fusion 
peptide binds the viral envelope to the endosomal membrane, allowing the viral proteins to be 
released into the cytoplasm of the host epithelial cell [28][29]. The acidic environment is also used 
for its hydrogen ions which are transferred into the virus particle through the M2 channel. These 
protons aid with the release of the viral proteins into the host cytoplasm by interfering with inner 
protein interactions [30]. 
 Viral replication inside cells 
All influenza RNA replication happens in the host cell nucleus, and so the first objective 
of the RNPs is to find the nucleus. This is directed by the RNPs’ nuclear localization signals [31]. 
Once in the nucleus, the viral mRNA is polyadenylated and capped to more closely resemble the 
host cells’ mRNA, and it is translated as such [32]. However the resulting RNPs are exported 
through viral components from the nucleus. 
After synthesis of the RNPs, they are packaged into virus particles to create infectious 
virions. The whole genome of the virus must be incorporated into each virus particle for it to be 
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fully infectious. Packing signals found on certain RNPs indicate that the viral packaging system is 
somewhat ordered to create more infectious particles [33][34]. 
 Viral release 
The newly-created virions bud at the cell membrane, with the virus’ M1 matrix playing a 
role in closing off the budding viruses [35]. HA continues to bind the virions to the SA on the cell 
membrane until NA cleaves the bonds to release the virions out of the cell, causing apoptosis [20]. 
NA also increases the infectivity of the new viruses by removing SA from the viral envelope, 
which helps prevent aggregation [36]. 
2.2. Challenges in current treatment methods for influenza A 
There exist many challenges for the present-day treatment of the influenza A virus. Though 
vaccination is thought to be the best method of coping with the virus due to its preventative nature, 
typical influenza vaccines are made to target only specific subtypes of influenza, and so are not 
effective across the broad spectrum. They also take time to prepare, are not effective in certain 
demographics of the population, and cannot adapt to antigenic changes in the virus throughout the 
season [37]. This leaves antiviral therapeutics. 
There are two main types of antiviral drugs currently on the market: NA inhibitors and M2 
channel inhibitors. The challenge with both is often virus resistance, which will be discussed 
further below. 
 NA inhibitors 
The two main NA inhibitors are oseltamivir (Tamiflu®) and zanamivir (Relenza®). Both 
work by inactivating the NA protein on the virus particle. This leads to the newly-made virions 
being unable to release themselves from the host cell, as described earlier. Instead of releasing, 
10 
they remain aggregated at the budding points on the cell membrane of the host cell, and thus reduce 
overall viral infectivity [38].  
Antiviral drug resistance is a growing problem, exacerbated by influenza A’s high 
mutational rates. Resistance can come from just one point mutation in a significant location in the 
M2 or NA protein [39], [40]. Oseltamivir-resistance has begun to grow amongst influenza A 
strains, most likely due to its common use as an easy-to-administer drug (oral administration) [41]. 
Generally, influenza A strains which exhibit resistance to oseltamivir are still susceptible to 
zanamivir, as the most common NA mutation which causes resistance affects the binding site of 
oseltamivir, not zanamivir [42]. However, zanamivir-resistance has been found in influenza B 
strains, indicating that it is only a matter of time before this spreads to influenza A [43]. 
 M2 channel inhibitors 
The two M2 channel inhibitors are amantadine (Symmetrel®) and rimantadine 
(Flumadine®), which act by blocking the M2 channel. This blockage inhibits viral replication in 
the host cell, as the M2 channel is used to transfer protons into the cell and fuse the endosomal 
membrane to the viral envelope, as described earlier.  
These drugs have been in use for four decades, and as such are now considered ineffective 
as when used alone as therapeutics for influenza A due to the high levels of resistance across the 
virus subtypes [44]. Resistance to one automatically confers resistance to the other, as they have 
very similar mechanisms of action [45]. It has reached the point where NA inhibitors are 
considered the only effective antiviral therapeutic, as M2 inhibitors now have worldwide influenza 




2.3. Advantages of NPs 
Nanoparticles, as mentioned earlier, are particles with at least one dimension on the 
nanoscale (10-9 m). Particles of this size often display very different properties than their bulk form 
due to their high surface area to volume ratio. This allows for a large degree of surface 
functionalization, thus favouring more reactivity with desired targets [48]. In the healthcare field, 
NPs have been used for drug delivery systems, biosensors, and as a combination of both drugs and 
delivery vehicle [49]–[51]. Some common advantages of NPs in this field include: high sensitivity 
and specificity for targets, ability to tune drug release, use lower doses, detect lower 
concentrations, and reduce costs [52]–[55]. 
NPs’ advantages make them strong candidates for influenza treatment. They can often 
subvert the restrictions on current antiviral therapies to create multivalent strategies to fighting 
influenza. Drugs which are toxic on their own can have lessened toxicity when bound to NPs, as 
lower doses can be used and less of it will travel to areas other than the target. Their size makes 
them ideal for influenza treatment, as they are likely to settle in the same parts of the pulmonary 
tract as the influenza virus upon inhalation. They are more suited to do so than microparticles, and 
are more likely to be retained in the pulmonary tract. In a study with carbon particles and shallow 
aerosol bolus inhalation in humans, 75% of particles sized <100 nm were retained in the lungs 
after 24 hourse, while only 10-20% of particles sized between 100 nm and 10 μm remained [56], 
[57]. 
NPs for treatment of influenza A can be approached in a variety of methods, from using a 
NP as the drug itself, to using it as simply a delivery vehicle, to a combination of both. A variety 
of materials can be used, such as different metals, metal oxides, and polymers. These methods are 
detailed in the next section. For a summary see Table 1. 
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Table 1. Summary of current research in NPs for treatment of influenza A 
Category Specific 
material 
Drug Mechanism References 
AgNPs AgNPs w/o 
coating 






AgNPs disrupt viral envelope, 
oseltamivir & zanamivir inhibit 
neuraminidase activity 
[62], [63] 
Amantadine AgNPs disrupt viral envelope, 
amantadine blocks M2 channel 
[64] 
AuNPs SA moieties No drug AuNPs acted as scaffold for 
various sialyllated moieties on 





Oseltamivir Modified oseltamivir and 
attached to AuNPs, retained 
inhibitory effects 
[68] 
Metal Oxides TiO2 No drug TiO2 disrupts viral envelope, 
destroys virus 
[69] 
Deoxyribozymes TiO2 delivers deoxyribozymes 
into cells,  inhibits viral 
replication 
[70] 
Silicate No drug Surfactant-modified nanoclay 
inhibited viral replicaton 
[71] 
Iron oxide No drug Glycine-coated iron oxide NPs 
inhibit antiviral activity 
[72] 




No drug PAMAM dendrimers coated 
with sialyllactose and linear 








zanamivir PEO-PCL polymersome coated 
with SA bind well to lectins, 






No drug α-glucuronic acid-linked cyclic 
dextrins with sialoglycoside 




2.4. Current use of NPs to treat influenza 
 Silver NPs 
Silver NPs (AgNPs) have been used in antimicrobial applications for some time now, and 
are excellent for this application due to their multivalent approach as antibiotics [77]. AgNPs’ 
main antimicrobial properties are its ability to leach silver ions, which interfere with bacterial cells 
and thus destroy them. However AgNPs are also able to interfere with bacteria in their whole 
particle form, thus creating a two-pronged approach [78]. Using a multivalent strategy limits the 
ability of the bacteria to gain resistance, and indeed resistance to silver/AgNPs has not yet surfaced 
among bacteria naturally [79]. The above-mentioned properties make AgNPs an important topic 
in the study for effective antivirals. 
AgNPs have been synthesized in a variety of ways, and used in a plethora of applications 
[80], [81]. Their antiviral application for influenza A specifically started in 2009 with Mehrbod et 
al. investigating their antiviral effects in vitro [60]. In this paper they determined the cytotoxicity 
of commercial AgNPs on Madin-Darby Canine Kidney (MDCK) cells to find the appropriate 
concentration to use on further tests with influenza A. This concentration was 0.5 μg/mL, and this 
was used in several in vitro tests with an H1N1 strain of influenza A. A hemagglutination inhibition 
assay was performed to check the AgNPs’ ability to inhibit the virus with red blood cells. A virus 
inhibition assay was done with MDCK cells and a colourimetric MTT assay, where confluent 
MDCK cells were infected with 100 TCID50 of the virus, allowed to bind for 1 h, and unbound 
virus was removed after with a wash. Then 100 μL of AgNPs were diluted with their medium and 
added to each well. The MTT assay involves the colour-changing ability of the MTT compound. 
Yellow MTT is changed to purple formazan in the presence of healthy cells due to their 
mitochondrial activity. If a colour change is not observed, it is assumed that the cells are not 
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healthy/they are dead [82]. In this case, MTT was added to the cells after the AgNPs, and 
absorbance values were measured. This showed an increase in cell viability with the addition of 
the AgNPs compared to virus-only cells, with 58.52% protection. Similar experiments with the 
additions of AgNPs before virus, and concurrently with virus, showed even higher protections. 
Other in vitro studies such as reverse transcription polymerase chain reaction (RT-PCR) confirmed 
these results. Merhbod et al. also elucidated the mechanism of AgNPs’ antiviral activity, where 
they estimate that the AgNPs are themselves attacking the disulfide bonds which hold the HA1 
and HA2 subunits of HA together. This would block the receptor binding sites on HA, rendering 
the virus inactive [60]. 
After this publication, many groups have studied the inhibitory effect of AgNPs on the 
influenza A virus. Publications generally dealt with in vitro tests described above such as the MTT 
assay, or the hemagglutination inhibition assay. Xiang et al. published papers dealing with naked 
AgNPs for both H1N1 and H3N2 [61], [83]. H1N1 studies were done only in vitro, where flow 
cytometry was used to determine the post-infection effect of 10 nm AgNPs on MDCK cells. The 
treatment reduced cell apoptosis by 9% compared to virus-only. Other tests including a 
hemagglutination inhibition assay showed the inhibitory effect of the AgNPs [83]. H3N2 studies 
were done both in vitro and in vivo. In vitro tests showed that MDCK cells infected with influenza 
virus for 2 hours prior to AgNPs being introduced showed an apoptosis rate of 13.58% +/- 4.86%, 
whereas the control virus-infected cells had a rate of 25.29% +/- 3.66%. In vivo tests were 
conducted with female BALB/c mice which were infected intranasally with 20 μL of H3N2 virus. 
AgNPs and oseltamivir were administered 24 hours after infection, and three times after to achieve 
a 5 mg/kg and 2 mg/kg dose of AgNPs and oseltamivir respectively (different groups of animals 
received different treatments). Mice treated with AgNPs had a 75% survival rate compared to the 
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control influenza group, and showed a reduction in lung virus titers by more than two orders of 
magnitude (comparable to the oseltamivir-treated group) [61]. This showed the ability of AgNPs 
to treat influenza A both in vitro and in vivo. 
As mentioned before, AgNPs have a wide variety of synthesis methods. Plant-based 
syntheses are growing in popularity for their safer chemistry and ease-of-use [80]. These methods 
certainly do not detract from the inhibitory effects of AgNPs on influenza, as demonstrated by 
Fatima et al. [59]. Cinnamon powder was used as the reducing agent, and their resulting AgNPs 
showed no significant toxic effects on Vero cells (up to 500 μg/mL). Both the cinnamon extract 
and the AgNPs were tested for their influenza inhibiting effects. Vero cells were infected with 104 
TCID50 and incubated for 2 hours. After this, unbound virus was removed and 100 μL of cinnamon 
extract or the AgNPs were added at varying concentrations. Cells were further incubated for 48 h, 
after which the MTT assay was carried out. A dose-dependence was established with the AgNPs, 
and at 200 μg/mL, the infection level of the cells was decreased to below 40%, compared to the 
100% of the virus-control cells. 
Apart from naked AgNPs, drug-AgNP conjugates have been tested for their efficacy. It is 
thought that synergistic effects could be found by combining common antiviral drugs with AgNPs, 
which here would act as both a delivery mechanism and a therapeutic. This is thought to be one 
method to avoid antiviral resistance, where using a multivalent approach can help. Three major 
antiviral drugs have been tested this way: oseltamivir (Ag@OTV), zanamivir (Ag@ZNV), and 
amantadine (Ag@AM) [62]–[64]. All three publications involved adhering the drug to the surface 
of AgNPs, though the chemistry is not explained. A number of in vitro tests were conducted, 
including hemagglutination inhibition assays, neuraminidase inhibitions assays, and MTT assays 
for cell viability. The neuraminidase inhibition assay was used specifically because oseltamivir 
16 
and zanamivir are neuraminidase inhibitors. All three publications had a drug-AgNP conjugate of 
2 nm in diameter, which was easily uptaken by cells. MTT assays were conducted with MDCK 
cells infected with H1N1 virus for 2 hours before washing off unbound virus and adding different 
concentrations of drug, regular AgNPs, or drug-AgNP conjugates for 24 hours. After this the MTT 
assay was conducted. Influenza-infected cells had a viability between 36-39%, AgNPs alone had 
61-65%, and amantadine, oseltamivir, and zanamivir had 56%, 59%, and 63% respectively. The 
combination therapies increased the viabilities drastically, with Ag@AM, Ag@OTV, and 
Ag@ZNV resulting in 90%, 90%, and 82.26% respectively. The therapies with drug-AgNP 
conjugates had strong results due to their multivalent approach to antiviral therapy. These papers 
also specify how the drug-AgNP conjugates are able to reduce the generation of reactive oxygen 
species, which is increased in influenza A-infected cells. They were also able to “rescue” cells 
from virus-induced apoptosis [62]–[64]. The results indicate an interesting future for these drug-
AgNP conjugates. 
In general, the AgNP field has come the farthest in antiviral therapies for influenza A, as it 
has seen some in vivo studies for treatment. More needs to be done in the in vivo area to continue 
this line of work. 
 Gold NPs 
Gold NPs (AuNPs) have been used in a variety of applications, from detection, to drug 
delivery, and many others [84]–[86]. They are well-known to be biocompatible and non-toxic, and 
as such, are often used for biomedical applications. Their use in antivirals is primarily as a scaffold 
upon which specific receptors can be bound to inhibit the influenza A virus, generally a version of 
SA. This is because the actual receptor of the HA protein on the virus is SA on epithelial cells, and 
so NPs with SA and Sa-like surface modifications are likely to be able to inhibit the virus. This 
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class of antiviral treatment has not come as far as that of AgNPs, where in vivo studies have been 
done, as well as multiple in vitro studies with treatment being a primary model. Many of the 
publications discussed below deal only with inhibition studies, though they are a promising first 
step to delivering AuNP-antiviral therapies for the future. AuNPs are currently used for a variety 
of applications [87]–[89]. 
The first study to look at the inhibitory effects of AuNP-mediated therapeutics for influenza 
A was by Papp et al., where 14 nm AuNPs were functionalized with glycerol dendrons with SA as 
the terminal groups [67]. The dendrons were covalently attached to the AuNPs by a thiol group, 
and two versions were made for testing; one with SA as the terminal group, and one with diol 
terminal groups. Their interaction with viral proteins such as HA was imaged by transmission 
electron microscopy (TEM), displaying multivalent binding. The cytotoxicity of the AuNPs was 
measured with a fluorescence staining test, where 100% viability was maintained in the tested 
MDCK cells compared to the control. A hemagglutination inhibition assay was conducted with 
red blood cells, and the functionalized AuNPs’ ability to inhibit viral infection was tested with a 
viral nucleoprotein assay. For this test, the H3N2 virus was incubated with the AuNPs with both 
SA and diol-terminated groups for 30 min, after which MDCK cells were exposed to the mixture 
at a multiplicity of infection (MOI) of 25 for five hours. Flow cytometry was used to determine 
the level of viral nucleoprotein in each sample, which is indicative of viral infection (higher 
amounts of protein correspond to higher levels of infection). The SA-AuNP sample reduced the 
infection by 40% compared to the virus-only control, while the diol-AuNP sample showed only a 
20% reduction [67]. This was the first conclusive evidence where AuNPs were used in a 
therapeutic for influenza A. 
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Since then a few papers have also looked at different methods to introduce SA groups onto 
AuNPs and study their effects on the influenza A virus. Zhang et al. used reversible addition-
fragmentation chain transfer to attach SA to their 17 nm AuNPs with a thiol group [65]. This 
inhibitor was tested for its ability to bind to different lectins which were representative of HA, and 
then its ability to bind to H1N1 influenza virions specifically. Dynamic light scattering (DLS) was 
used to characterize the sizes of the compounds while TEM visualized the binding. TEM showed 
the specificity of binding between the virus and the SA-terminated AuNPs, compared to a lactose-
terminated control. Lectin binding was shown through DLS, where different sizes described 
different compounds. Inhibition was reported in the cases of SA-AuNPs compared to the lactose 
control [65]. Feng et al. described a method to introduce thiosialosides onto AuNPs and other 
metals, where the oxygen of the glycoside bond of the sialoside was replaced by a sulfur group 
[66]. This prevents interaction of the SA acid with NA, which would try to cleave it off otherwise. 
The formulations with the highest inhibitory activity for H1N1 were a 20 nm AuNP with 9.8 μM 
SA on it (hemagglutination inhibition titre of 64) and a 50 nm AgNP with 13.7 μM SA 
(hemagglutination inhibition titre of 128) [66]. 
A last example of using AuNPs for antiviral work utilizes oseltamivir in conjunction with 
AuNPs to create “TamiGold” [68]. Stanley et al. decorated the surface of 2 and 14 nm AuNPs with 
a modified oseltamivir carboxylate form (oseltamivir phosphonate), which retains similar 
inhibitory activity to the drug itself. The 14 nm version was simply used for TEM studies to show 
interaction with the inactivated H1N1 virus, whereas the 2 nm version was used to check inhibitory 
effects with a neuraminidase inhibition assay (as oseltamivir binds to the neuraminidase protein). 
IC50 values were calculated for the 2 nm TamiGold from the inhibition assay, with 14.7 nM and 
12.3 nM for 2 oseltamivir-sensitive strains and 5.3 μM and 14.1 μM for oseltamivir-resistant 
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strains. These concentrations are the minimum concentrations of oseltamivir phosphonate needed 
to inhibit the virus. Control samples made with methylphosphonate AuNPs instead of oseltamivir 
phosphonate showed no inhibitory effects, ruling out unspecific binding [68]. 
Overall, AuNPs have been shown to provide a versatile scaffold for carrying other 
therapeutics to treat influenza A. Their biocompatibility and biodegradability make them ideal for 
targeted drug delivery, and their size and customizability for functionalization make them ideal for 
influenza A treatment. Current options have progressed very far even by in vitro standards, with 
inhibition being the majority of the tests. Further work with live viruses and cells is needed to 
determine the therapeutic effect of the AuNP-delivered treatments. Eventually in vivo work must 
be done to further prove the underlying claims from inhibition studies. 
 Metal oxide NPs 
Apart from metals, there are many other bases for NP formulations. Metal oxides have seen 
increasing popularity for biomedical applications. In their bulk form, these metal oxides are often 
toxic to humans. However when nanoscale versions are used at low concentrations, metal oxides 
such as TiO2, ZnO, and SiO2 have seen success in a variety of therapies [90]–[92]. 
Naked TiO2 has been studied for its antiviral properties by Mazurkova et al. [69]. Tests 
were done to see if TiO2 was able to inhibit the influenza A virus through a mechanism that did 
not involve its photocatalytic abilities. H3N2 at a concentration of 9.5 lg TCID50/mL was mixed 
with TiO2 NPs (4-10 nm) and incubated for different time periods. Increased incubation time led 
to more destruction of the viral envelope, as seen by TEM. The inhibition effect was seen by adding 
the TiO2 NP-influenza mixture to MDCK cells and doing a hemagglutination assay with chicken 
red blood cells 20 hours after incubation. The inhibitory activity of the TiO2 NPs was largest at 2 
and 7 mg/mL (equal in both, showing a plateau), and was seen irrespective of the lighting 
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conditions (ultraviolet, daylight, or dark). With both concentrations, the virus titer was reduced 
from over 6 lg TCID50/mL to 0 lg TCID50/mL. This antiviral effect of TiO2 is attributed to its 
ability to penetrate and destroy the viral envelope, as it is a lipoprotein membrane similar to that 
of eukaryotic cells, which TiO2 can enter fairly easily. Low concentrations will have to be used so 
as to not have adverse effects on non-target cells [69]. 
Metal oxides as carriers for nucleic acid therapies are an interesting combination, as they 
may be able to take advantage of the carrier being therapeutic as well (similar to AgNPs from 
before). Deoxyribozymes are a class of nucleic acid therapeutics which can cleave complementary 
RNA strands irreversibly, thereby acting as a gene silencer [93]. Repkova et al. studied the effects 
of coupling deoxyribozymes non-covalently to TiO2 NPs coated with polylysine to create a 
nanocomposite. Antiviral efficacy of the nanocomposite was assessed with MDCK cells infected 
with H5N1 at a MOI of 0.1. Treatment of these cells with the nanocomposite resulted in inhibition 
by a factor of approximately 3000, which was an order of magnitude higher than the control 
delivery vehicle lipofectamine. Inhibition was measured by viral titer measurements after 
treatment with the nanocomposite and control [70].  
Kumar et al. looked at the antiviral effects of glycine-coated iron oxide NPs [72]. In vitro 
studies including plaque inhibition assays, RT-PCR, and MTT assays were conducted. Treatment 
with the NPs within 24 hours of infection of MA104 cells by a 0.5 MOI of H1N1 resulted in an 8-
fold reduction of viral RNA [72].  
Liang et al. went a different route, investigating the antiviral potency of exfoliated 
montmorillonite clay [71]. The fully exfoliated clay was called nanoscale silicate platelets, and 
was coated with sodium dodecyl sulfate (SDS), an anionic surfactant to create NSQc. The addition 
of the surfactant served to lessen the cytotoxicity of the nanoclay. NSQc was found to have 
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inhibitory properties for multiple virus types (Japanese encephalitis, dengue) along with influenza. 
Plaque-formation assays were conducted where the H1N1 virus was mixed with NSQc, along with 
other versions with different surfactant amounts, then added to BHK-21 cells. Unbound virus 
particles were washed off after 2 hours of incubation, then agarose-containing medium was laid 
over the cells for 4 days. Crystal-violet stain was used to determine plaque growth. NSQc and 
NSQc(A30) showed high inhibitory effects, where the viral titer was reduced by an order of 
magnitude (A30 had a 70:30 ratio of surfactant to platelets). NSQc(A50) showed no inhibitory 
effects, from which it can be derived that the surfactant played a major role in antiviral inhibition 
(A50 had a 50:50 ratio of surfactant to platelets). The main mechanism of action is thought to be 
the electrostatic interactions between the negative surfactant SDS on the nanoscale platelet, and 
the positively charged viral envelopes of the viruses studied [71]. 
Metal oxides display an interesting combination of therapeutic-delivery vehicle/sole 
therapeutic. TiO2 has been studied in vitro fairly extensively for its inhibitory effects and ability 
to treat influenza A in infected cells. As long as cytotoxicity is kept in check, future work in vivo 
could expand the field greatly. Some new players include the nanoclay and iron oxide NPs, still 
more in their infancy. Further in vitro work is warranted before stepping into in vivo. 
 Polymeric NPs 
Polymeric NPs have been used for drug delivery in a variety of forms, including micellar, 
dendrimer, linear, and many others [94]–[96]. Their high degree of customizability allows the use 
of biodegradable materials and targeting ligands which can allow for smooth delivery with few 
toxic side-effects.  
Dendrimers are a specific class of polymeric NP with branched chains growing out of a 
core. The therapeutic component can either be non-covalently bonded at the core or on the surface, 
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waiting to be released once at the target site, or it can be covalently bonded with stable bonds, 
which could be cleaved upon reaching the desired location, or used to attach the whole dendrimer 
and employ steric hindrance [97], [98]. Kwon et al. created a polyamidoamine (PAMAM) 
dendrimer with multivalent properties due to its functionalization with 6’sialyllactose [73]. They 
performed a number of in vitro studies to test its inhibitory effect against the H1N1 virus. The 
dendrimer was pre-mixed with the virus before addition to MDCK cells, after which ELISA was 
conducted to determine the IC50. In general, highly-branched versions of the dendrimer with 
specific spacing requirements showed increased inhibitory activity (3.4 μM was the lowest IC50 
achieved). Surface plasmon resonance was used to determine the binding between the HA trimer 
and the dendrimer. In vivo studies were conducted for a prevention-type system, where the 
dendrimers were administered intranasally to mice before infection. Lung viral titer was lower 
with the dendrimer administration compared to the control, though this is more a prevention aspect 
[73]. Another study using dendritic branches comes from Nazemi et al., who created a 
polymersome made of poly(ethylene oxide)-polycaprolactone (PEO-PCL) with sialiodendrons 
(dendritic branches with SA-terminal groups) [75]. The resulting compound has a two-pronged 
approach, where the outer shell of the polymersome can bind to HA through the SA, and the inner 
core can encapsulate an antiviral drug and carry it to the target site. They chose to incorporate 
zanamivir, and tested the ability of the compound to bind to the Limax flavus lectin (similar to HA) 
and encapsulate and release zanamivir. The entire dendritic-polymersome compound resulted in a 
2000-fold increase in binding affinity compared to simply SA. This study is still in the early stages, 
but there is promise for its multivalent approach to inhibiting influenza. 
On the other side, Bhatia el at have created a linear polyglycerol sialoside which performs 
far better than its dendritic sister [74]. Multiple in vitro experiments were conducted in order to 
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determine the inhibitory performance of each type, both linear and dendritic. Cell viability was 
conducted with MDCK II cells to determine the cytotoxicity of the compounds (insignificant). 
Hemagglutination inhibition assays, infection inhibition assays, viral nucleoprotein assays, and 
others were conducted to show the inhibitory effects of the linear vs. dendritic polysialosides. Most 
of the studies were conducted with pre-incubation of the virus (H3N2) and polysialoside together 
before addition to MDCK cells. However one experiment was conducted with infection of MDCK 
cells (MOI 0.01) with H3N2 and H7N1 for 45 mins before addition of the polysialoside. The linear 
polysialoside reduced the viral titer by 4 orders of magnitude compared to 3 for the dendritic 
version. Further studies were conducted in vivo as well, but in a preventative measure (samples 
were administered before virus infection) [74]. This study shows an interesting example of when 
linear polymeric NPs can perform better than their dendritic counterparts, though most studies 
discussed earlier show the opposite. 
Finally, another example of SA-functionalized NPs comes in the form of α-glucuronic 
acid-linked cyclic dextrins by Ogata et al. [76]. The backbone of the NP consists of cyclic dextrins 
with highly branched α-glucuronic acid and sialoglycoside groups on the outer shell. The dextrins 
offer a high degree of functionalization (allowing for multivalent binding), biocompatibility due 
to their makeup from sugars, and high aqueous solubility [99]. A hemagglutination inhibition assay 
was conducted to determine the minimum inhibitory concentration required to completely inhibit 
hemagglutination with red blood cells. The compound was tested with different amounts of 
sialoglycoside groups, and it was found that the sample with the highest amounts of SA on the 
outside inhibited hemagglutination with the lowest concentration (0.09 nM), about 240-fold better 
than fetuin which also binds well to the influenza virus [76]. This study is still in its infancy, as 
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only inhibition tests with erythrocytes have been conducted, but the results are promising for future 
in vitro and in vivo tests. 
Polymeric NPs, through their many attractive properties, have been extensively studied for 
drug delivery in humans. Much of this can extend to influenza A treatment, where the polymeric 
NPs range from acting simply as a drug delivery vehicle, to being a scaffold for physical blocking, 
to a combination therapy of both. Generally this field has not been fully studied in terms of 
influenza A treatment; more in vitro and in vivo studies can be done to ensure effectiveness. Linear 
vs dendritic NPs have traditionally gone in favour of dendritic for their inhibitory effects, though 
as seen above this is not always the case. More study is generally needed in this field. 
2.5. Conclusions/Outlook 
Influenza A is a growing problem, with pandemics, antiviral resistance, and new strains 
appearing every year. Current therapies either have already failed (M2 channel inhibitors) or are 
showing signs of imminent failure (neuraminidase inhibitors) in the solo treatment approach. New 
methods are needed to properly treat influenza A, and NPs can be a major component of the 
solution. From metals to metal oxides, to polymeric and beyond, NPs are able to transcend typical 
therapeutic limitations due to their size, surface-functionalization abilities, and multivalent 
approaches to treatment (sometimes acting as both carrier and therapeutic). AgNPs show this 
characteristic quite well, where the antibacterial effects are able to carry over to antiviral (though 
through a different mechanism). AuNPs act as an excellent scaffold, often for SA moieties. Metal 
oxides can combine both vehicle and therapeutic at times. Polymeric NPs can deliver treatment/act 
as a scaffold for blocking, similar to AuNPs. Overall the AgNP field has come the farthest in 
starting in vivo studies, though this may be because the antibacterial properties had been well 
studied beforehand. The other fields have different in vitro studies, though some only come as far 
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as inhibition as opposed to treatment. Polymeric NPs, with their biocompatibility, 
biodegradability, and ability to utilize a multivalent approach to combatting influenza, are a field 























Chapter 3. Establishing binding kinetics of MNPs 
3.1. Determination methods 
As seen in section 2.4, one of the typical first-steps in establishing the inhibitory effects of 
a possible antiviral compound is determining the binding kinetics between said compound and 
hemagglutinin, or conducting a hemagglutination inhibition assay. Though this is a straightforward 
method for many studies, it is not possible to use for the MNPs’ novel proposed method for 
antiviral activity. This is because MNPs bind specifically to the SAs on the mucus membrane 
(through mucoadhesion), and by doing so can block the binding of the virus and deliver antiviral 
drugs. They do not affect the virus’ ability to hemagglutinate red blood cells, as they do not bind 
to the HA protein. Therefore, new methods were needed to determine the binding abilities of the 
MNPs, and compare them to that of influenza. 
Mucoadhesion has been measured through a variety of methods throughout the years. 
Using sheep mucus strips, Swamy et al. measured how many of their particles remained bound to 
the strips after a wash and calculated percent mucoadhesion [100]. Chary et al. measured the force 
needed to detach their mucoadhesive polymers from sheep intestines [101]. Lim et al. measured 
the mucociliary transport rate of their particles on frog palates, and calculated a value in relation 
to graphite particles [102]. These methods all require specialized materials such as animal organs, 
and do not measure a direct binding constant. Springsteen et al. measured an indirect binding 
constant using a three-component fluorescence system, but used a fairly complicated method of 
analysis [103]. The processes mentioned above do not fit the requirements for the needed tests, 
which are to calculate a direct binding constant to compare for influenza-SA, and to use a facile 
method. These conditions can be met by a combination of LSPR and fluorescence studies with 
rigorous design parameters. 
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First, LSPR was used to observe the real-time binding of MNPs to mucin, and compare 
this to PLA-Dex NPs (control samples with no PBA on them). This is an in vitro test which 
validates the PBA as the mucoadhesive component of the MNPs. Mucin is used to more accurately 
mimic in vivo studies. Many iterations and parameters were studied for this test before the design 
reported below was finalized. 
After the qualitative studies with LSPR were conducted, quantitative studies were needed 
to establish a binding constant value for MNPs with SA to be able to compare to literature values 
of influenza-SA. The SA-hemagglutinin dissociation constant has been widely studied, and found 
to be 2-3 mM [104], [105]. This translates to a KA of approximately 333-500 M
-1. Therefore in 
order to be a competent antiviral therapeutic, the MNPs would need a binding constant >500 M-1 
with SA. This is covered by fluorescence studies. 
While fluorescence studies were underway for determining binding constants, it was 
noticed that this same study could be used for an in vitro test as a predictor of mucoadhesion in 
vivo. The theory was that lower amounts of PBA conjugation would decrease mucoadhesion of 
the MNPs. By changing the amount of PBA on the MNPs, the binding constant value would change 
proportionally. A study was developed (with preliminary data) which uses both LSPR and 
fluorescence as a means to predict mucoadhesion, which could be applied to minimize in vivo 
studies in the future. 
3.2. Materials and methods 
 Materials 
Acid-terminated PLA (MW: 20 kDa) was purchased from Lakeshore Biomaterials (USA) 
and washed with methanol to remove monomer impurities. Dextran (MW: 10 kDa), 3-
Aminophenylboronic acid monohydrate (PBA), sodium periodate (NaIO4), glycerol, sodium 
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cyanoborohydride (NaCNBH3), N-acetylneuraminic acid (SA), bovine submaxillary mucin, and 
CsA were purchased from Sigma Aldrich (Canada). LSPR sensor chips were purchased from 
Nicoya Lifesciences (Canada). 
 MNP preparation 
The amphiphilic block copolymer PLA-Dex was prepared using a previously reported 
method [106]. NPs were formed by self-assembly of the amphiphilic block copolymer through 
nanoprecipitation, after which they were surface-modified with PBA in two steps: the hydroxyl 
groups of the dextran surface of the NPs were oxidized in the presence of NaIO4, and the aldehyde 
groups were then reacted with the amino groups of PBA using reductive amination in the presence 
of NaBH3CN[106]. The size of the resulting MNPs was measured by dynamic light scattering 
(DLS). 
MNPs with different mol% of PBA on the dextran monomer were fabricated for the 
correlating in vitro & in vivo mucoadhesion study. Initial PBA amounts of 0, 10, 20, and 40 mg 
were used.   
 LSPR Studies 
The binding of the MNPs to mucin was qualitatively measured by LSPR on an OpenSPR 
system (Nicoya Lifesciences). LSPR is a phenomenon of AuNPs (as well as other materials), 
where the intrinsic resonance of the AuNPs can shift when they are coated with a substance. 
Optical measurements can be taken when light is shone on the AuNPs, and these measurements 
increase upon coating of the AuNPs. This increase can be used to determine binding kinetics 
between various receptors and ligands [107]. This was used to qualify in real-time the binding 
between MNPs and control PLA-Dex NPs with mucin, and compare the two. To this end, 100-nm 
AuNP sensors were purchased and cleaned by successive rinses of deionized (DI) water, ethanol, 
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acetone, and isopropanol, before being dried with nitrogen gas. DI water was used as the running 
buffer throughout the experiment, flowing over the sensor surface at 20 μL/min. Bovine 
submaxillary mucin was dissolved at 10 mg/mL in DI water and vortexed for five minutes. 200 
μL of the mucin mixture was injected onto the sensor surface in the OpenSPR at 20 μL/min for 15 
min to ensure even coating. 200 μL of 1 mM sodium hydroxide (NaOH) was injected three times 
after the mucin injection to remove unbound mucin from the surface, after which the injection port 
was cleaned with DI water and purged with air. After a stable baseline was reached, 200 μL of 
MNPs or control PLA-Dex NPs was injected onto the sensor surface at 20 μL/min for 5 min, after 
which the injection port was cleaned with DI and purged with air. The mucin surface was 
regenerated after each sample injection by injecting 200 μL of 1 mM NaOH onto the surface to 
remove the samples.  
 Fluorescence studies 
To quantitatively evaluate the mucoadhesive properties of MNPs, the covalent interaction 
between the PBA grafts on the surface of the MNPs and SA molecules was studied. The covalent 
complexation between PBA and SA quenches the intrinsic fluorescence of the PBA molecules. 
Thus, the interaction between PBA and SA can be quantified by analysing the relative fluorescence 
intensities of MNPs in the presence of varying concentrations of SA. The relative fluorescence 
data can then be analysed to determine the Stern-Volmer binding constant, KSV, using the Stern-
Volmer equation as seen in Equation 1 [108], 
𝐼0
𝐼⁄ = 1 + 𝐾𝑆𝑉 × [𝑄] 
Equation 1: Stern-Volmer equation 
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where I0 is the fluorescence intensity of the MNPs sample without SA ([SA] = 0 mM), I is the 
fluorescence intensity of MNPs with SA, and [Q] is the concentration of the quenching agent, SA. 
The KSV value is determined by calculating the slope of the linear fit. 
This method was first verified by measuring the KSV of free PBA and SA for comparison 
with literature values. PBA solutions in DI water were mixed with SA to achieve a constant final 
concentration of PBA (10 μM) with varying SA concentrations (0, 1, 5, 10, 25, and 50 mM). The 
mixtures were vortexed for 30 seconds before measurement in a spectrofluorometer (type LS-100, 
Photon Technology International, Canada). The samples were excited at 298 nm, and the emission 
scan from 310 to 450 nm was obtained for each sample. The relative fluorescence data was then 
analyzed to determine KSV using the Stern-Volmer equation. The resulting KSV was compared to 
KA values for PBA-SA from literature for confirmation of the method’s validity for measurement 
of MNPs-SA. 
After the initial fluorescence study, the experiment was repeated with MNPs. MNP 
suspensions were mixed with SA solutions to achieve a constant final concentration of MNPs (50 
µg/ml) with varying SA concentrations (0, 0.01, 0.02, 0.04, 0.08, 0.12, 0.16, and 0.32 mM). The 
mixtures were vortexed for 30 seconds before measurement, with the same parameters used. The 
relative fluorescence data was then analyzed to determine KSV using the Stern-Volmer equation. 
3.3. Results & Discussion 
 MNP characterization 
The MNPs were fabricated with 46.1 ± 0.001 mol % of PBA on the dextran monomer. The 
diameter of the MNPs was 50.2 ± 0.6 nm, while the control PLA-Dex NPs was 60.5 ± 0.9 nm. 
This diameter is well-suited for pulmonary applications, as it is less likely to be cleared quickly by 
mucociliary clearance as mentioned earlier. 
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 LSPR study 
MNPs and control NPs were injected at 0.3 mg/mL onto the mucin-coated surface of the 











Both samples show similar binding curves initially, where the signal increases sharply due to the 
addition of a new substance onto the sensor surface, regardless of its binding ability. After the 
initial increase however, changes can be seen. The MNP sample continues to increase throughout 
the duration of the injection, albeit less sharply than before. This shows that more of the sample is 
binding to the mucin surface throughout the injection. The control NP sample remains steady for 
the duration of the injection, showing that though sample is being continually added to the surface, 
it is not being retained by the mucin coating. Finally after the end of the injection, both samples 
see a decrease in the signal. The MNP sample steadies itself at a higher baseline than the control 








Figure 6. MNP binding (black) on a bovine submaxillary mucin-coated AuNP 
surface, compared to control NP (red) binding. 
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MNP sample has bound to the mucin surface, as the alteration in the baseline signal is both steady 
and higher than the initial level prior to injection. 
Studies involving mucin are very important to be able to more closely mimic in vivo 
conditions. Mucin is the largest component of the mucus membrane, and is made up of high 
molecular weight glycoproteins with sialic acid as the terminal residue. Bovine submaxillary 
mucin is an easy-to-obtain source of mucin which is similar to mucin found in pulmonary systems. 
This study definitively shows the PBA as the source of mucin-binding for the MNPs, gives a real-
time window into binding in a more qualitative manner, and does so in a more accurate in vitro 
setting. 
 Initial fluorescence study 
The Stern-Volmer method described above was tested for its efficacy in determining an 
accurate binding constant between PBA-SA before it was used for the MNPs. The emission spectra 
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Figure 7. In vitro interaction between PBA and SA. Emission spectra of PBA (50 μg/mL) with 
various concentrations of SA (0 to 50 mM) at room temperature, λex = 298 nm (left). Relative 
fluorescence as a function of SA concentrations. I0 and I represent the fluorescence intensity in 
the absence and presence of SA respectively. Data were fit according to the Stern−Volmer 
Equation (right) 
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The emission spectra on the left show decreasing fluorescence intensity with increasing SA 
concentrations, as expected for SA’s quenching abilities. Further concentrations of SA were not 
used as the compound had reached a saturation point (see section 3.3.4 for more details). I0/I vs. 
[SA] was plotted for every SA concentration used, as shown in the graph on the right. Linear 
regression was used to fit the data to the Stern-Volmer equation, which gave a KSV value of 30.3 
M-1. Literature values place the KA for PBA-SA between 11.4 M
-1 – 37.6 M-1 depending on the 
method used to determine it [109], [103], [110]. KSV is known as a binding constant, though 
depending on the type of fluorescence quenching occurring, it can represent different constants. 
Static quenching (when the quencher inhibits the excited state from being formed, through a 
covalent bond for example) yields a KSV which is equal to KA, the association constant. Dynamic 
quenching (when the quencher interferes with the excited state after formation) yields a KSV which 
is its own binding constant, similar but not equivalent to KA [108]. The PBA-SA quenching occurs 
through photoinduced electron transfer, where the electron excited in the PBA is transferred to SA 
instead of being emitted. This is static quenching, and this allows comparisons between the KSV 
value determined from this method and the literature sources of KA for PBA-SA binding [111], 
[112]. The value obtained here (30.3 M-1) is quite comparable with those reported in literature, and 
as such validates this method for use with MNPs and SA. 
 MNPs fluorescence KSV 
Upon validation of the fluorescence method with PBA-SA, the same experiment was 
conducted for MNPs-SA to determine their KA. The emission spectra and resulting data analysis 














The emission spectra (left) show decreasing fluorescence intensity with increasing SA 
concentrations as expected. Further concentrations were not used as the compound had reached a 
saturation point. I0/I vs [SA] was plotted for each SA concentration, and the data was fit to the 
Stern-Volmer equation through linear regression. This yielded a KSV (=KA) value of 5646.7 +/- 
140.2 M-1. This is a very high value for KA, much higher than what has been previously reported 
for PBA and PBA compounds with SA. This is likely due to the high number of PBA molecules 
decorating the surface of the MNPs. Previous PBA compounds which measure the KA with sialic 
acid typically have only one PBA moiety per compound [108], [110], whereas MNPs have a high 
number (15.2 mol% on the dextran monomer). This makes MNPs much more likely to bind to SA, 
as they have more binding sites available per nanoparticle. This is promising proof for MNPs’ 
ability to target influenza, as the typical SA-HA bond has a KA ranging from 333 – 500 M
-1. MNPs’ 
order-of-magnitude higher KA vouches for their ability to bind to the mucus membrane much more 













































𝐼⁄ = 1 + 𝐾𝑆𝑉 × [𝑄] 
K
SV
 = 5464.7 +/- 140.2 M
-1
  
Figure 8. In vitro interaction between MNPs and SA. Emission spectra of MNPs (50 μg/mL) 
with various concentrations of SA (0 to 1.62 mM) at room temperature, λex = 298 nm (left). 
Relative fluorescence as a function of SA concentrations. I0 and I represent the fluorescence 
intensity in the absence and presence of SA respectively. Data were fit according to the 
Stern−Volmer Equation (right) 
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 A note on saturation points mentioned above: the analysis for KSV ends at the SA 
concentration after which the MNP solution becomes saturated with quencher (i.e. adding more 
quencher does not change the fluorescence intensity by much). If concentrations of SA above the 
saturation point are used, linear regression is not accurate and the resulting KSV value is very 





















































































 = 5563.8 M
-1
  
R2 = 0.9821 
K
SV
 = 1324.6 M
-1
  
R2 = 0.6552 
Figure 9. SA concentrations used past the saturation point skew results. Top left and right show the 
emission spectra and analysis of properly analysed MNP-SA binding, where R2 value is close to 1. 
Bottom left and right show the same data with additional SA concentrations past the saturation point, 
where large increases in SA do not change the fluorescence much. This results in skewed KSV data shown 
through the low R2 value. 
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The emission spectra in the bottom left clearly shows very little difference in the fluorescence 
intensity of samples with SA concentrations above saturation point (in this case, 1.62 mM). These 
high concentrations cause a plateau to be formed in the analysis on the right, which renders linear 
regression inaccurate. The low R2 value (shifting from 0.9821 previously to 0.6552) attests to this. 
Careful consideration must be taken to avoid using concentrations above the saturation point 
(which is usually noted qualitatively from the emission spectra and the graphical analysis, and 
quantitatively from the R2 value), or else the reported data will be inaccurate (as in this case the 
Ksv changed from 5563.8 M-1 to 1324.6 M-1). 
 Correlating in vitro & in vivo mucoadhesion 
The results from the previous studies confirmed that PBA was indeed the mucoadhesive 
component of the MNPs, and that it was possible to quantify the binding between MNPs and SA. 
This prompted another query: as binding between MNPs and SA is the definition of mucoadhesion, 
was it possible to accurately predict the mucoadhesive capabilities of MNPs in vivo by doing in 
vitro tests? The in vitro tests were conducted to determine if they could detect small changes in 
mucoadhesion. MNPs with varying amounts of PBA functionalization (0, 10, 20, and 40 mg 
starting material) were nanoprecipitated and used for LSPR and fluorescence tests. The 10 mg 
starting material yielded 19.8 mol% PBA/dextran monomer, the 20 mg yielded 25.7 mol%, and 




LSPR showed overall an increased signal for increasing amounts of PBA in all stages of injection 
(the initial spike, the sustained injection period, and the end of the injection). Baseline stabilization 
post-injection of sample fell in line with the PBA values: 0 mg PBA had no increase in baseline, 
20 mg PBA had a slight increase in baseline, and 40 mg PBA had the highest increase in baseline. 
This qualitatively shows real-time binding between the MNPs with different mol% of PBA to 
mucin on the AuNP surface, thus showing the LSPR’s ability to detect different amounts of 
mucoadhesion. 
 This is followed up by quantitative studies with fluorescence in the graph on the right 
(conducted the same way as the previous studies). Linear regression revealed increasing KA values 
for increasing amounts of PBA to start with when making the MNPs. The original MNP recipe 
yielded a KA value of 5365.5 M
-1, the 25.7 mol% PBA gave 1218.7 M-1, and the 19.8 mol% PBA 
gave 236.02 M-1.  
 The two studies combined give a promising preview to what could be an innovative method 


















MNPs 46.2 mol% 
 
MNPs 25.7 mol% 
 
NPs 0 mol%  
Binding 
Figure 10. Utilizing in vitro studies to predict mucoadhesion of MNPs in vivo. LSPR 
graph (left) shows increased binding with increasing amounts of PBA. Analysis for 
KA (right) shows increased KA values for increasing PBA amounts. 
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data presented here is still fairly preliminary, but the ability of the in vitro methods to be able to 
detect small changes in mucoadhesive capability could minimize animal studies in the future. 
3.4. Conclusions 
This chapter was dedicated to elucidating the binding kinetics between MNPs and SA in 
order to both better understand the binding model, and compare a binding constant value with 
literature values of SA-HA. LSPR opened a revealing window to the real-time binding which 
occurs between MNPs and mucin, and allowed a comparison with control PLA-Dex NPs and 
mucin. Using mucin was crucial to better mimic in vivo environments. It also allowed another 
confirmation of PBA as the mucoadhesive component in the MNPs. Fluorescence KSV studies 
defined a facile quantitative measure of the binding between MNPs and SA, and the nature of 
binding between MNPs and SA allowed a more direct comparison with KSV = KA. The measured 
KA of MNPs (5464.7 +/- 140.2 M
-1) was much higher than that reported in literature for SA-HA 
(333 – 500 M-1). This affords a key advantage to MNPs in the quest to effectively treat influenza 
A, in that it is likely able to block binding between the influenza A virus to its target receptor SA. 
Though the studies were initially designed as replacements for the hemagglutination 
inhibition assays conducted by many other publications, the in vitro tests became quite useful in 
their own right. After rigorous design regarding SA concentrations, coating parameters, etc. the 
result is a relatively facile set of tests. These were also expanded to being able to determine small 
differences in mucoadhesivity of the MNPs in vitro, and thus potentially remove the need for in 
vivo studies by predicting the capabilities themselves. This is preliminary work however. 
The next step for the MNPs is to examine their properties after aerosolization, a process 
which will have to occur for their antiviral mechanism to take place (inhalation of MNPs). They 
are tested with CsA, a model drug. 
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Chapter 4. Characterizing aerosolized MNPs 
4.1. MNP aerosolization and characterization 
The next phase in determining MNPs’ feasibility as an antiviral system was to determine 
their response to aerosolization. This is an important step, as their characteristics and morphology 
would ideally remain on par with their pre-aerosolized form, in order to retain their excellent ability 
for delivery and binding to mucosal membranes. The properties that were tested were morphology 
through TEM, drug encapsulation efficiency, drug weight loading, and drug release profiles 
through HPLC. 
CsA is the active ingredient in Restasis®. Its hydrophobicity lends itself to being a good 
candidate for encapsulation by the MNPs in their hydrophobic PLA interior core. CsA also has 
uses in the respiratory tract, where it is used to treat idiopathic pulmonary fibrosis and improve 
lung function [113], [114]. This chapter uses CsA as the model drug to study how aerosolization 
affects the MNPs’ ability to encapsulate and release drugs, though future studies will use more 
influenza-specific drugs such as oseltamivir. 
4.2. Materials and methods 
 Materials 
MNP formulation materials are the same as those is section 3.2.1. CsA was purchased from 
Sigma-Aldrich (Canada). TEM grids (F/C 400 mesh Cu) were purchased from Ted Pella (USA). 
Phosphotungstic acid was purchased from Fisher (Canada). 
 MNP preparation + drug encapsulation 
Blank MNPs were prepared as described in section 3.2.2. The encapsulation of CsA in the 
MNPs was performed by nanoprecipitation. 1 mL of DMSO containing the PLA-Dex-PBA 
polymer (15 mg/mL) and CsA (varied concentration) was slowly added into 10 mL of Millipore 
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water under mild stirring for self-assembly of MNPs carrying the drugs. This was repeated once 
to ensure a final batch volume of 22 mL. The MNPs−CsA mixture was then syringe filtered (pore 
size = 200 nm) to remove NP or drug aggregates, and dialyzed against water to remove some of 
the free drugs and DMSO from the mixture.  
 MNP characterization 
The sizes of the nanoparticles were determined using DLS, while the morphology of MNPs 
with no CsA (blank MNPs) was determined by TEM.  Grids were prepared with 6.5 μL of sample 
and dried overnight, after which they were negatively stained with 20 mg/mL phosphotungstic 
acid.  
The encapsulation efficiency and drug loading of CsA in the MNPs was determined using 
high-performance liquid chromatography (HPLC; C18 HPLC column, ACN/H2O 80:20 as the 
mobile phase with UV-absorption detection at 210 nm). 2 mL of the MNP-CsA solution was 
centrifuged in an Amicon Centrifugal Unit (MWCO = 10 kDa, Millipore Sigma) for 10 minutes at 
8000 rpm to separate free CsA from the MNP-CsA compounds. The MNP-CsA compounds were 
then re-suspended in 10 mL acetonitrile before being run through HPLC. Labelling is as follows: 
MNPs-CsA-(wt%) where wt% is the drug weight% compared to the polymer. For example, MNPs-
CsA-30% has 30 weight% of the polymer. Encapsulation efficiency was calculated as per Equation 
2, where the actual concentration of drug measured in the sample is divided by the theoretical 
concentration of drug.  
𝐸𝐸% =  
[𝐶𝑠𝐴]𝑎𝑐𝑡𝑢𝑎𝑙
[𝐶𝑠𝐴]𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙
 × 100% 
Equation 2. Encapsulation efficiency 
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Drug loading was found by multiplying the encapsulation efficiency (not percentage) by the 
theoretical drug loading, as shown in Equation 3. 
𝐷𝐿% = 𝐸𝐸 ×  𝐷𝐿%𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 
Equation 3. Drug Loading 
CsA’s in vitro release profile from MNP-CsA was conducted through dialysis with DI as 
the release medium. 4 mL of sample was injected into a Slide-A-Lyzer dialysis cassette (MWCO: 
20 kDa) and dialyzed against 120 mL of DI water at 37°C under mild stirring. 1 mL of the release 
medium was removed at each pre-determined time point (1, 3, 6, 12, 24, 48, 72, 96, and 120 h) to 
quantify the CsA release with HPLC, while 1 mL of fresh DI water was added to maintain a 
consistent volume. 
 Aerosolization procedure 
Aerosolization of the MNPs was conducted with a Pari Nebulizer (LC® Sprint Reusable 
Nebulizer). MNPs or MNPs-CsA solution was added to the cup of the nebulizer post-dialysis to 
remove free drug and DMSO. The outlet was modified to suit the volume requirements of the 
experiment; while the nebulizer was designed for direct inhalation of the aerosols formed, the 
experiments required the samples to be in a liquid state for further characterization. To achieve 
this, the main exit point of the nebulizer was blocked off with parafilm, forcing the aerosols to 
climb to the top of the nebulizer where they were condensed back into liquid form and escaped 
into a centrifuge tube. 8 mL of MNPs-CsA yielded approximately 4-6 mL of aerosolized MNPs-
CsA (MNPs-CsA-AER). All characterization methods were employed on both MNPs-CsA and 




4.3. Results & Discussion 
 TEM morphology characterization 
The morphology of blank MNPs was examined pre- and post-aerosolization to determine 
if aerosolization had any adverse effects. Changes to morphology can skew encapsulation and 


















Figure 11. TEM images of blank MNPs pre and post-aerosolization. MNPs pre-
aerosolization (top left: 500 nm scale bar, top right: 100 nm scale bar), MNPs post-




The zoomed out images on the left show similarities between pre- and post-aerosolization MNPs 
on a larger scale, with similar size spheres making up the grid. Once magnified, the images on the 
right show similar sizes and shapes, indicating the lack of adverse effects on morphology from 
aerosolization. This clears the path for blank MNPs’ use in inhalation-based therapy; the next step 
determined how aerosolization affected their drug-encapsulating properties. 
 DLS, encapsulation efficiency, and drug loading 
CsA was encapsulated in the MNPs at two weight percentages: 30 and 120%. The extremes 
of drug concentrations were explored to allow a better characterization of the MNPs’ drug loading 
abilities. The samples were measured by DLS for their size and polydispersity (PDI), and HPLC 
for their encapsulation efficiency (EE) and drug loading (DL). Results are shown in Table 2. 
Table 2. Characterization of MNPs-CsA and MNPs-CsA-AER 
 DLS (nm) PDI EE (%) DL (%) 
Blank MNPs 50.6 0.085 - - 
MNPs-CsA-30% 69.1 0.063 77.54 23.36 
MNPs-CsA-30%-AER 287.7 0.359 62.62 18.79 
MNPs-CsA-120% 135.4 0.088 84.28 101.14 
MNPs-CsA-120%-AER 517.9 0.167 84.29 101.15 
 
DLS results showed increasing size with increasing drug concentration in both MNPs-CsA 
and MNPs-CsA-AER. The sizes increased somewhat after aerosolization, possibly due to 
aggregation from the condensation of the aerosols. Though not ideal, it is not a cause of worry as 
the encapsulation efficiencies and drug loading are relatively unaffected by aerosolization. Both 
the 30 and 120 wt% showed high encapsulation efficiencies, and aerosolization seemed to keep 
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them relatively stable (more so for the higher wt%, likely due to the larger amount of drug available 
in the solution). Indeed, the 120% had no real change in encapsulation efficiency, staying at 84%. 
The drug loading calculation shows the actual drug/polymer ratio which was loaded in the MNPs, 
and so is ideally 30 or 120%. The results show very high drug loading for both MNPs-CsA 
samples, very close to the theoretical drug loading. The results were again virtually unchanged 
post-aerosolization, highlighting the lack of negative effects from aerosolization on the MNPs.  
 Release study 
Finally, the release profile of MNPs-CsA pre- and post-aerosolization was evaluated. DI 
water was used as the release medium as used in other such studies [115]. The profiles of all four 











As can be seen, the 30 wt% samples generally released more than their 120 wt% 
counterparts. This may be due to the increased amount of hydrophobic drug in the 120 wt% sample 






























Figure 12. Release profile of MNPs-CsA and MNPs-CsA-AER at two different 
wt% (30 and 120%). Measurements were taken over a 5 day period. 
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concentration, thus releasing less of the cumulative drug amount. Both concentrations show an 
initial burst release (to different degrees) and then steady, sustained release over the measured time 
points. Focusing on simply pre- and post-aerosolized MNPs shows remarkably similar trends in 
release profiles. Aerosolization seems to have little effect on the MNPs’ ability to release 
encapsulated drugs. 
4.4. Conclusions 
This chapter examined the effect of aerosolization on blank MNPs and MNPs carrying a 
model drug (CsA). The ability to withstand aerosolization is an important parameter for MNPs as 
their intended target, influenza in the lungs, will be best reached by inhalation (the same manner 
in which influenza infection occurs). 
Blank MNPs responded well to aerosolization with no real morphological changes as seen 
by TEM. Though DLS on CsA-encapsulated MNPs showed an increase in diameter, the size 
changes did not affect the MNPs’ abilities to encapsulate and release CsA. Encapsulation 
efficiencies and drug loading were quite high in both CsA weight percents which were tested, and 
the release profile into DI was quite steady and similar between pre- and post-aerosolized samples. 
CsA was used as a model drug due to its use in aiding pulmonary function, its hydrophobic 
nature, and its ability to be encapsulated in MNPs as examined previously for ocular delivery. As 
this model drug is not affected by the aerosolization procedure, the next step to this study will be 






Chapter 5. Conclusions & Future Work 
5.1. Conclusions 
The goal of this thesis work was to examine the possibility of using mucoadhesive 
nanoparticles as antiviral therapeutics for the influenza A virus. Its similar mechanism of use in 
ocular drug delivery lent itself to exploration in pulmonary delivery. To that end, a thorough 
literature review was conducted to determine the current uses of nanoparticles in influenza A 
treatment. Based off this, it was decided to go forward with testing MNPs as polymeric NPs had 
not been fully explored in their capacity as antiviral therapeutics.  
The MNPs were first tested for their ability to bind to the mucus membrane (and sialic acid 
specifically) through localized surface plasmon resonance and fluorescence studies. These 
experiments cemented the MNPs’ mechanism of mucoadhesion (PBA binding covalently to sialic 
acid) and resulted in qualitative and quantitative binding kinetic data for the MNPs through the 
Stern-Volmer equation. The KA value for MNPs with sialic acid was determined to be 5464.7 +/- 
140.2 M-1, which is far higher than the literature values of 333-500 M-1 for sialic acid-
hemagglutinin. This gave confidence to the initial hypothesis of MNPs’ candidacy for antiviral 
therapeutics. During these experiments, another use for binding kinetics studies was discovered: 
the potential to predict mucoadhesion from LSPR and fluorescence in vitro as opposed to 
conducting in vivo work. The methods were able detect differences in binding constants and 
general binding in MNPs with different amounts of PBA attached, a first-step in this process.  
The next step in determining the MNPs’ viability for antiviral therapeutics was to check 
for changes in key properties and characteristics after aerosolization. Aerosolization is a major 
component for effective antiviral treatment, and morphology, drug encapsulation properties, and 
release profiles of the MNPs were tested and compared for pre- and post-aerosolization MNPs. 
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CsA was used as a model drug due to its previous encapsulation in MNPs and its use in aiding 
pulmonary function. Morphology remained similar for blank MNPs pre- and post-aerosolization, 
and though sizes did increase, encapsulation efficiencies, drug loading, and release profiles did not 
differ significantly for MNPs encapsulating CsA.  
5.2. Future Work 
The research objectives outlined in section 1.2 were met through this body of work, and 
paved the way for future studies. 
The next step for assessing MNPs’ viability as antiviral therapeutics will be to load antiviral 
drugs and observe their properties. Oseltamivir, due to its hydrophobic nature, would be an 
excellent candidate to attempt encapsulation. Once encapsulation has been achieved, drug release 
propertied should be determined. Using oseltamivir in this way allows a multivalent approach to 
fighting influenza, where MNPs act as both a drug-carrier and an inhibitor themselves. 
An in vitro study is recommended to properly assess the antiviral capabilities of MNPs 
with oseltamivir against live virus. Many examples of these are shown in Chapter 2, where MDCK 
cells are infected with live virus strains and treated with the antiviral compound. A suggestion to 
improve the typical study would be to layer the MDCK cells with mucin to more properly mimic 
in vivo conditions. 
Simulations could be used to model the binding between MNPs and sialic acid, and 
compare it to hemagglutinin and sialic acid. This would impart a greater understanding of the bond, 
and provide methods of improvement. 
The preliminary data from the correlating in vitro and in vivo mucoadhesion study shows 
promise in predicting mucoadhesive capabilities. This study should be furthered with more 
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replicates of the current data, and finally in vivo studies to corroborate the differences detected by 
the in vitro method.  
Finally, an in vivo study should be conducted for aerosolized MNPs to determine their 
bioavailability in the lungs. Theoretically, MNPs should be able to settle well into the pulmonary 
tract due to their nanoscale size. Their mucoadhesive function should also afford some protection 
from rapid clearance. An in-depth murine in vivo study would confirm these hypotheses, and 
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